Common Contracts
2 similar Clinical Trial Collaboration Agreement contracts by Exelixis, Inc.
ContractClinical Trial Collaboration Agreement • May 5th, 2020 • New York
EX-10.2 3 exel20170331exhibit102.htm EXHIBIT 10.2 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Exhibit 10.2 CLINICAL TRIAL COLLABORATION AGREEMENT This CLINICAL TRIAL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of February 24, 2017 (the “Effective Date”) by and between Exelixis, Inc., a Delaware corporation, located at 210 East Grand Avenue, South San Francisco, CA 94080 (“Exelixis”) and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Exelixis and BMS may be referred to herein individually as a “Party,” or collectively as the “Parties.” RECITALS WHEREAS, the Parties wish to collaborate with each other to sponsor one or more clinical trials of a combination therapy using Exelixis’s
CLINICAL TRIAL COLLABORATION AGREEMENTClinical Trial Collaboration Agreement • May 1st, 2017 • Exelixis, Inc. • Services-commercial physical & biological research • New York
This CLINICAL TRIAL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of February 24, 2017 (the “Effective Date”) by and between Exelixis, Inc., a Delaware corporation, located at 210 East Grand Avenue, South San Francisco, CA 94080 (“Exelixis”) and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Exelixis and BMS may be referred to herein individually as a “Party,” or collectively as the “Parties.”
